Laguna Hills, CA – According to filings with the U.S. Securities and Exchange Commission, PreludeDx is raising $20,000,001.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Daniel Forche played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PreludeDx
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patients treatment decision. Our mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system. We realize that every sample that comes through our laboratory has a patient behind it and it is our job to ensure that we handle each sample with care and provide results back to the patient and physician in a timely manner. PreludeDx exists to take care of the needs of our patients. We will put quality systems and processes first and foremost as we provide the highest quality results to our patients and physicians. PreludeDx will strive to find new innovative tools and processes that assist patients and physicians for the better management of cancer.

To learn more about PreludeDx, visit http://preludedx.com/

Contact:
Daniel Forche, Chief Executive Officer
949-348-1188
dforche@preludedx.com
https://www.linkedin.com/in/dan-forche-174439/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved